Bluebird Bio (NASDAQ: BLUE) reported Q1 EPS of ($0.44), $0.12 worse than the analyst estimate of ($0.32). Revenue for the quarter came in at $6.3 million versus the consensus estimate of $6.23 million.

For earnings history and earnings-related data on Bluebird Bio (BLUE) click here.